Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

Efficacy of Glecaprevir and Pibrentasvir in Patients with Genotype 1 Hepatitis C Virus Infection with Treatment Failure after NS5A Inhibitor Plus Sofosbuvir Therapy.

Lok AS, Sulkowski MS, Kort JJ, Willner I, Reddy KR, Shiffman ML, Hassan MA, Pearlman BL, Hinestrosa F, Jacobson IM, Morelli G, Peter JA, Vainorius M, Michael LC, Fried MW, Wang GP, Lu W, Larsen L, Nelson DR.

Gastroenterology. 2019 Aug 8. pii: S0016-5085(19)41199-2. doi: 10.1053/j.gastro.2019.08.008. [Epub ahead of print]

PMID:
31401140
2.

Prevalence and Impact of Hepatitis E Virus Infection Among Persons With Chronic Hepatitis B Living in the US and Canada.

McGivern DR, Lin HS, Wang J, Benzine T, Janssen HLA, Khalili M, Lisker-Melman M, Fontana RJ, Belle SH, Fried MW.

Open Forum Infect Dis. 2019 Apr 9;6(5):ofz175. doi: 10.1093/ofid/ofz175. eCollection 2019 May.

3.

Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.

Evon DM, Sarkar S, Amador J, Lok AS, Sterling RK, Stewart PW, Reeve BB, Serper M, Reau N, Rajender Reddy K, Di Bisceglie AM, Nelson DR, Golin CE, Lim JK, Fried MW.

J Hepatol. 2019 Sep;71(3):486-497. doi: 10.1016/j.jhep.2019.04.016. Epub 2019 May 13.

PMID:
31096006
4.

Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection.

Brahmania M, Lombardero M, Hansen BE, Terrault NA, Lok AS, Perrillo RP, Belle SH, Di Bisceglie AM, Feld JJ, Lee WM, Fried MW, Janssen HLA; Hepatitis B Research Network.

Clin Gastroenterol Hepatol. 2019 Feb 8. pii: S1542-3565(19)30143-0. doi: 10.1016/j.cgh.2019.02.005. [Epub ahead of print]

PMID:
30743006
5.

HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition.

Brouwer WP, Zhao Q, Hansen BE, Lau D, Khalili M, Terrault NA, Di Bisceglie AM, Perrillo RP, Fried MW, Wong D, Feld JJ, Belle SH, Janssen HLA; Hepatitis B Research Network.

Clin Gastroenterol Hepatol. 2019 Jan 7. pii: S1542-3565(19)30012-6. doi: 10.1016/j.cgh.2018.12.039. [Epub ahead of print]

PMID:
30630104
6.

Chronic hepatitis B virus monoinfection at a university hospital in Zambia.

Vinikoor MJ, Sinkala E, Kanunga A, Muchimba M, Nsokolo B, Chilengi R, Wandeler G, Mulenga J, Chisenga T, Bhattacharya D, Saag MS, Foster G, Fried MW, Kelly P.

World J Hepatol. 2018 Sep 27;10(9):622-628. doi: 10.4254/wjh.v10.i9.622.

7.

A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study.

Evon DM, Stewart PW, Amador J, Serper M, Lok AS, Sterling RK, Sarkar S, Golin CE, Reeve BB, Nelson DR, Reau N, Lim JK, Reddy KR, Di Bisceglie AM, Fried MW.

PLoS One. 2018 Aug 1;13(8):e0196908. doi: 10.1371/journal.pone.0196908. eCollection 2018.

8.

The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial.

Proeschold-Bell RJ, Evon DM, Makarushka C, Wong JB, Datta SK, Yao J, Patkar AA, Mannelli P, Hodge T, Naggie S, Wilder JM, Fried MW, Niedzwiecki D, Muir AJ.

Contemp Clin Trials. 2018 Sep;72:73-85. doi: 10.1016/j.cct.2018.07.003. Epub 2018 Jul 10.

PMID:
30006024
9.

Novel patient-reported outcomes (PROs) used in a pilot and feasibility study of a Cognitive Behavioral Coping Skills (CBCS) group intervention for patients with chronic hepatitis C.

Evon DM, Golin CE, Ruffin R, Ayres S, Fried MW.

Pilot Feasibility Stud. 2018 Jun 27;4:92. doi: 10.1186/s40814-018-0285-5. eCollection 2018.

10.

A real-world observational cohort of patients with primary biliary cholangitis: TARGET-primary biliary cholangitis study design and rationale.

Levy C, Bowlus CL, Carey E, Crawford JM, Deane K, Mayo MJ, Kim WR, Fried MW.

Hepatol Commun. 2018 Mar 23;2(5):484-491. doi: 10.1002/hep4.1173. eCollection 2018 May.

11.

Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort.

Kwo P, Fried MW, Reddy KR, Soldevila-Pico C, Khemichian S, Darling J, Zamor PJ, Napoli AA, Anduze-Faris B, Brown RS Jr.

Hepatol Commun. 2018 Feb 27;2(4):354-363. doi: 10.1002/hep4.1156. eCollection 2018 Apr.

12.

Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection.

Wang GP, Terrault N, Reeves JD, Liu L, Li E, Zhao L, Lim JK, Morelli G, Kuo A, Levitsky J, Sherman KE, Frazier LM, Ramani A, Peter J, Akuskevich L, Fried MW, Nelson DR.

Sci Rep. 2018 Feb 16;8(1):3199. doi: 10.1038/s41598-018-21303-2.

13.

Parsing the guidelines on guidelines: Balancing sensibility and conflict of interest.

Zucker SD, Fried MW.

Hepatology. 2018 Sep;68(3):798-800. doi: 10.1002/hep.29810. Epub 2018 May 16. No abstract available.

PMID:
29431195
14.

Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy.

Evon DM, Amador J, Stewart P, Reeve BB, Lok AS, Sterling RK, Di Bisceglie AM, Reau N, Serper M, Sarkar S, Lim JK, Golin CE, Fried MW.

Aliment Pharmacol Ther. 2018 Apr;47(7):1001-1011. doi: 10.1111/apt.14531. Epub 2018 Jan 29.

15.

Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.

Lim JK, Liapakis AM, Shiffman ML, Lok AS, Zeuzem S, Terrault NA, Park JS, Landis CS, Hassan M, Gallant J, Kuo A, Pockros PJ, Vainorius M, Akushevich L, Michael L, Fried MW, Nelson DR, Ben-Ari Z; HCV-TARGET Study Group.

Clin Gastroenterol Hepatol. 2018 Nov;16(11):1811-1819.e4. doi: 10.1016/j.cgh.2017.12.037. Epub 2018 Jan 3.

PMID:
29306043
16.

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.

Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hézode C, Felizarta F, Reindollar RW, Gordon SC, Pianko S, Fried MW, Bernstein DE, Gallant J, Lin CW, Lei Y, Ng TI, Krishnan P, Kopecky-Bromberg S, Kort J, Mensa FJ.

Hepatology. 2018 Apr;67(4):1253-1260. doi: 10.1002/hep.29671. Epub 2018 Jan 30.

17.

Development and Pilot-Testing of a Cognitive Behavioral Coping Skills Group Intervention for Patients with Chronic Hepatitis C.

Evon DM, Golin CE, Ruffin R, Fried MW.

Contemp Clin Trials Commun. 2017 Jun;6:85-96. doi: 10.1016/j.conctc.2017.03.008. Epub 2017 Apr 2.

18.

Controversies in hepatitis C therapy: Reactivation of hepatitis B virus.

Lieber SR, Fried MW.

Clin Liver Dis (Hoboken). 2017 Oct 31;10(4):87-92. doi: 10.1002/cld.665. eCollection 2017 Oct. Review. No abstract available.

19.

An Efficient, Large-Scale Survey of Hepatitis C Viremia in the Democratic Republic of the Congo Using Dried Blood Spots.

Parr JB, Lodge EK, Holzmayer V, Pepin J, Frost EH, Fried MW, McGivern DR, Lemon SM, Keeler C, Emch M, Mwandagalirwa K, Tshefu A, Fwamba F, Muwonga J, Meshnick SR, Cloherty G.

Clin Infect Dis. 2018 Jan 6;66(2):254-260. doi: 10.1093/cid/cix771.

20.

Public-Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals.

Mishra P, Florian J, Peter J, Vainorius M, Fried MW, Nelson DR, Birnkrant D.

Gastroenterology. 2017 Sep;153(3):626-631. doi: 10.1053/j.gastro.2017.07.025. Epub 2017 Jul 27. No abstract available.

PMID:
28757271
21.

Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis.

Poordad F, Nelson DR, Feld JJ, Fried MW, Wedemeyer H, Larsen L, Cohen DE, Cohen E, Mobashery N, Tatsch F, Foster GR.

J Hepatol. 2017 Oct;67(4):700-707. doi: 10.1016/j.jhep.2017.06.011. Epub 2017 Jun 21. Review.

22.

Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B.

Hassan MA, Kim WR, Li R, Smith CI, Fried MW, Sterling RK, Ghany MG, Wahed AS, Ganova-Raeva LM, Roberts LR, Lok ASF; Hepatitis B Research Network.

Am J Epidemiol. 2017 Aug 1;186(3):356-366. doi: 10.1093/aje/kwx064.

23.

Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.

Saxena V, Khungar V, Verna EC, Levitsky J, Brown RS Jr, Hassan MA, Sulkowski MS, O'Leary JG, Koraishy F, Galati JS, Kuo AA, Vainorius M, Akushevich L, Nelson DR, Fried MW, Terrault N, Reddy KR.

Hepatology. 2017 Oct;66(4):1090-1101. doi: 10.1002/hep.29258. Epub 2017 Sep 4.

24.
25.

Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment.

Evon DM, Golin CE, Stewart P, Fried MW, Alston S, Reeve B, Lok AS, Sterling RK, Lim JK, Reau N, Sarkar S, Nelson DR, Reddy KR, Di Bisceglie AM.

Contemp Clin Trials. 2017 Jun;57:58-68. doi: 10.1016/j.cct.2017.03.013. Epub 2017 Mar 22.

26.

Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.

Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS.

Ann Intern Med. 2017 May 2;166(9):637-648. doi: 10.7326/M16-2575. Epub 2017 Mar 21. Review.

27.

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.

Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Gordon SC, Flamm SL, Fried MW, Bernstein DE, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ.

Hepatology. 2017 Aug;66(2):389-397. doi: 10.1002/hep.29081. Epub 2017 Apr 10. Erratum in: Hepatology. 2017 Nov;66(5):1708.

28.

Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders.

Walsh CE, Workowski K, Terrault NA, Sax PE, Cohen A, Bowlus CL, Kim AY, Hyland RH, Han B, Wang J, Stamm LM, Brainard DM, McHutchison JG, von Drygalski A, Rhame F, Fried MW, Kouides P, Balba G, Reddy KR.

Haemophilia. 2017 Mar;23(2):198-206. doi: 10.1111/hae.13178. Epub 2017 Jan 25.

PMID:
28124511
29.

What's Important to the Patient? Informational Needs of Patients Making Decisions About Hepatitis C Treatment.

Evon DM, Golin CE, Stoica T, Jones RE, Willis SJ, Galanko J, Fried MW.

Patient. 2017 Jun;10(3):335-344. doi: 10.1007/s40271-016-0207-7.

30.

Opciones terapéuticas para los pacientes con hepatitis C crónica y fracaso terapéutico previo.

Shah ND, Fried MW.

Clin Liver Dis (Hoboken). 2016 Nov 10;8(Suppl 1):S25-S29. doi: 10.1002/cld.594. eCollection 2016 Nov. Review. No abstract available.

31.

All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database.

Reddy KR, Lim JK, Kuo A, Di Bisceglie AM, Galati JS, Morelli G, Everson GT, Kwo PY, Brown RS Jr, Sulkowski MS, Akuschevich L, Lok AS, Pockros PJ, Vainorius M, Terrault NA, Nelson DR, Fried MW, Manns MP; HCV-TARGET Study Group.

Aliment Pharmacol Ther. 2017 Jan;45(1):115-126. doi: 10.1111/apt.13823. Epub 2016 Oct 28.

32.

Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.

Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, Kuo A, Lok AS, Shiffman ML, Ben Ari Z, Akushevich L, Vainorius M, Sulkowski MS, Fried MW, Nelson DR; HCV-TARGET Study Group.

Gastroenterology. 2016 Dec;151(6):1131-1140.e5. doi: 10.1053/j.gastro.2016.08.004. Epub 2016 Aug 24.

33.

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.

Welzel TM, Nelson DR, Morelli G, Di Bisceglie A, Reddy RK, Kuo A, Lim JK, Darling J, Pockros P, Galati JS, Frazier LM, Alqahtani S, Sulkowski MS, Vainorius M, Akushevich L, Fried MW, Zeuzem S; HCV-TARGET Study Group.

Gut. 2017 Oct;66(10):1844-1852. doi: 10.1136/gutjnl-2016-311609. Epub 2016 Jul 13.

34.

Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study.

Feld JJ, Maan R, Zeuzem S, Kuo A, Nelson DR, Di Bisceglie AM, Manns MP, Sherman K, Frazier LM, Sterling R, Mailliard M, Schmidt M, Akushevich L, Vainorius M, Fried MW.

Clin Infect Dis. 2016 Sep 15;63(6):776-783. doi: 10.1093/cid/ciw387. Epub 2016 Jun 19.

35.

Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.

Saxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT, Liapakis A, Nelson DR, Fried MW, Terrault NA; HCV-TARGET.

Liver Int. 2016 Jun;36(6):807-16. doi: 10.1111/liv.13102. Epub 2016 Mar 24.

36.

Treatment options of patients with chronic hepatitis C who have failed prior therapy.

Shah ND, Fried MW.

Clin Liver Dis (Hoboken). 2016 Feb 26;7(2):40-44. doi: 10.1002/cld.532. eCollection 2016 Feb. Review. No abstract available.

37.

Hepatitis C Virus Outbreaks in Hemodialysis Centers: A Continuing Problem.

Weber DJ, Rutala WA, Fried MW.

Infect Control Hosp Epidemiol. 2016 Feb;37(2):140-2. doi: 10.1017/ice.2015.311. No abstract available.

PMID:
26813313
38.

Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.

Brown RS Jr, O'Leary JG, Reddy KR, Kuo A, Morelli GJ, Burton JR Jr, Stravitz RT, Durand C, Di Bisceglie AM, Kwo P, Frenette CT, Stewart TG, Nelson DR, Fried MW, Terrault NA; Hepatitis C Therapeutic Registry Research Network Study Group.

Liver Transpl. 2016 Jan;22(1):24-33. doi: 10.1002/lt.24366.

39.

HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape.

Reau N, Fried MW, Nelson DR, Brown RS Jr, Everson GT, Gordon SC, Jacobson IM, Lim JK, Pockros PJ, Reddy KR, Sherman KE.

Liver Int. 2016 Apr;36(4):488-502. doi: 10.1111/liv.12993. Epub 2015 Nov 22. Review.

40.

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.

Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, Morelli G, Darling JM, Feld JJ, Brown RS, Frazier LM, Stewart TG, Fried MW, Nelson DR, Jacobson IM; HCV-TARGET Study Group.

Gastroenterology. 2016 Feb;150(2):419-29. doi: 10.1053/j.gastro.2015.10.013. Epub 2015 Oct 21.

41.

Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.

Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, Fried MW, Pol S, Rockstroh JK, Terrault NA, Wiktor S.

Gut. 2015 Nov;64(11):1824-33. doi: 10.1136/gutjnl-2015-310421. Review.

42.

High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity.

Johansson S, Talloen W, Tuefferd M, Darling J, Fanning G, Fried MW, Aerssens J.

Liver Int. 2016 Mar;36(3):344-52. doi: 10.1111/liv.12932. Epub 2015 Sep 6.

43.

Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients.

Johansson S, Talloen W, Tuefferd M, Darling JM, Scholliers A, Fanning G, Fried MW, Aerssens J.

Aliment Pharmacol Ther. 2015 Nov;42(9):1111-21. doi: 10.1111/apt.13389. Epub 2015 Aug 28.

44.

Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia.

Forns X, Poordad F, Pedrosa M, Berenguer M, Wedemeyer H, Ferenci P, Shiffman ML, Fried MW, Lovell S, Trinh R, Lopez-Talavera JC, Everson G.

Liver Int. 2015 Nov;35(11):2358-62. doi: 10.1111/liv.12931. Epub 2015 Sep 6.

45.

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.

Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, Fried MW, Terrault NA, O'Leary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, Brown K, Kwo P, Pungpapong S, Korenblat KM, Muir AJ, Teperman L, Fontana RJ, Denning J, Arterburn S, Dvory-Sobol H, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N; SOLAR-1 Investigators.

Gastroenterology. 2015 Sep;149(3):649-59. doi: 10.1053/j.gastro.2015.05.010. Epub 2015 May 15.

46.

Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.

Sterling RK, Kuo A, Rustgi VK, Sulkowski MS, Stewart TG, Fenkel JM, El-Genaidi H, Mah'moud MA, Abraham GM, Stewart PW, Akushevich L, Nelson DR, Fried MW, Di Bisceglie AM.

Aliment Pharmacol Ther. 2015 Apr;41(7):671-85. doi: 10.1111/apt.13095. Epub 2015 Jan 28.

47.

Elevated AST-to-platelet ratio index is associated with increased all-cause mortality among HIV-infected adults in Zambia.

Vinikoor MJ, Sinkala E, Mweemba A, Zanolini A, Mulenga L, Sikazwe I, Fried MW, Eron JJ, Wandeler G, Chi BH.

Liver Int. 2015 Jul;35(7):1886-92. doi: 10.1111/liv.12780. Epub 2015 Jan 22.

48.

Bacteremia and malaria in Tanzanian children hospitalized for acute febrile illness.

Lundgren IS, Heltshe SL, Smith AL, Chibwana J, Fried MW, Duffy PE.

J Trop Pediatr. 2015 Apr;61(2):81-5. doi: 10.1093/tropej/fmu069. Epub 2014 Dec 9.

49.

Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies.

Manns MP, Fried MW, Zeuzem S, Jacobson IM, Forns X, Poordad F, Peeters M, Fu M, Lenz O, Ouwerkerk-Mahadevan S, Jessner W, Scott JA, Kalmeijer R, De La Rosa G, Sinha R, Beumont-Mauviel M.

J Viral Hepat. 2015 Apr;22(4):366-75. doi: 10.1111/jvh.12346. Epub 2014 Nov 3.

PMID:
25363449
50.

Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.

Gordon SC, Muir AJ, Lim JK, Pearlman B, Argo CK, Ramani A, Maliakkal B, Alam I, Stewart TG, Vainorius M, Peter J, Nelson DR, Fried MW, Reddy KR; HCV-TARGET study group.

J Hepatol. 2015 Feb;62(2):286-93. doi: 10.1016/j.jhep.2014.08.052. Epub 2014 Sep 10.

Supplemental Content

Loading ...
Support Center